- A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia
- Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous
- Chelation Therapy of Iron Overload With Pyridoxal Isonicotinoyl Hydrazone
- Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
- Hydroxyurea to Treat Beta-Thalassemia (Cooley’s Anemia)
- Lucky Iron Fish Home Fortification of Iron
- Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
- Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
Clinical Trials
- A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
- Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium
- Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients – ECULISHU
- Erythropoietin in Hemolytic Uremic Syndrome
- Haemolytic Uraemic Syndrome in Childhood: Clinical, Cognitive and Psychological Aspects
- Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- International Registry and Biorepository for TMA(Thrombotic Microangiopathy)
- Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4
- Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital
- Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS
- Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome
- Rituximab in Patients With Relapsed or Refractory TTP-HUS
- Shiga Toxin Producing Escherichia Coli (STEC) Volume Expansion
- Study of ‘Vascular Competence’ Profile and Endothelial Activation in the Hemolytic Uremic Syndrome in Children and Adults
- Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis
- The Plasma Large-Volume Exchange RCT
- The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)
- Usefulness of a Diagnostic Algorithm to Diagnose Thrombotic Microangiopathies in Pregnancy
- A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients
- A Prospective Clinical Study of Ruxolitinib and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome.
- A Study of TQ05105 Tablets in Subjects With Hemophagocytic Lymphohistiocytosis（HLH）
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Emapalumab in Adult Patients With HLH
- A Study to Investigate the Safety and Efficacy of an Anti-IFNγ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis
- Assessing the Presence of CT-DNA in Lymphoma Associated HLH
- Chidamide Combines With VP-16 and Methylprednisolone in the Treatment of HLH
- Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic Lymphohistiocytosis
- DEP Combine With PD-1 Antibody as an Initial Treatment for EBV-HLH
- DEP-Ru Regimen as a Salvage Therapy for HLH
- Diagnostic Biomarkers for Adult Hemophagocytic Lymphohistiocytosis in Critically Ill Patients (HEMICU)
- Efficacy and Safety of Venetoclax Combined With Dexamethasone and Etoposide in HLH
- Etoposide in the First-line Treatment of Adult EBV-HLH
- Evaluate the Efficacy and Safety of PEG-rhG-CSF in Patients With Hemophagocytic Syndrome
- Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
- L-DEP as an Initial Treatment for EBV-HLH
- L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
- L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
- L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH
- Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody
- Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.
- Pilot Study of Etoposide-based Therapy and Hematopoietic Cell Transplantation for Hemophagocytic Lymphohistiocytosis
- Prospective Cohort for Adult Hemophagocytosis
- Response Prediction in EBV-HLH Using Metabonomics Analysis
- Retrospective Study of Immunotherapy Related Toxicities in Children and Adults With Cancer
- Rituximab Monotherapy for EBV-HLH and CAEBV
- Ruxolitinib as a Salvage Therapy for Hemophagocytic Lymphohistiocytosis
- Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)
- Ruxolitinib Combined With Dexamethasone for HLH
- Sensitivity and Specificity of Cytokines in the Diagnosis of Lymphoma-associated HLH
- Splenectomy as a Treatment for Patient With Relapsed Haemophagocytic Lymphohistiocytosis of Unknown Etiology
- Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
- Study to Evaluate Interferon Gamma (IFNγ) and Other Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH)
- The Prognostic and Diagnostic Value of Ferritin in Critically Ill Patients With Special Focus on Underlying Hemophagocytic Lymphohistiocytosis
- Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
- Treatment of Familiar Lymphohistiocytosis
- Treatment Protocol for Hemophagocytic Lymphohistiocytosis 2004
- Trial of DA-EPOCH Regimen for NHL With HLH
- Use Of A Response-Adapted Ruxolitinib-Containing Regimen For The Treatment Of Hemophagocytic Lymphohistiocytosis
- 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece
- A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health
- A Clinical Phenotype Based Individualized Prophylaxis in Chinese Hemophilia A Children
- A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
- A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors
- A Factor IX Gene Therapy Study (FIX-GT)
- A Feasibility Study to Collect Data in Patients With Haemophilia
- A Gene Therapy Study for Hemophilia B
- A Gene Transfer Study for Hemophilia A
- A Long-Term Follow-Up Study in Severe Hemophilia A Subjects Who Received BMN 270 in a Prior BioMarin Clinical Trial (270-401)
- A Long-Term Follow-Up Study of Haemophilia B Patients Who Have Undergone Gene Therapy
- A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A
- A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
- A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A
- A Non-interventional Retrospective Study of the Current Treatment Practice in European Haemophilia Care
- A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
- A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects
- A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
- A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
- A Post Approval Commitment Study to Gain More Information on How Safe and Effective KOVALTRY is in Chinese Children, Adolescents /Adults With Severe Hemophilia A
- A Post Marketing Surveillance Study for ADYNOVATE in South Korea
- A Progressive Resistance Training Program in Patients With Haemophilia
- A Prospective Study Evaluating Seroprevalence and Seroconversion of Antibodies Against Adeno-associated Virus (AAV)
- A Prospective Study to Collect High-Quality Documentation of Bleeds, Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A Treated With Standard-of-Care Treatment
- A Research Study Investigating Mim8 in Adults and Adolescents With Haemophilia A With or Without Inhibitors
- A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
- A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A
- A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A (FRONTIER 4)
- A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
- A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B
- A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B
- A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
- A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
- A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
- A Safety, Tolerability, and Pharmacokinetics Study of a Single Intravenous Injection of Recombinant Coagulation Factor VIII Fc – Von Willebrand Factor – XTEN Fusion Protein (rFVIIIFc-VWF-XTEN) (BIVV001) in Previously Treated Adults With Severe Hemophilia A (EXTEN-A)
- A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers
- A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
- A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543
- A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
- A Study Comparing Factor Level and Inhibitor Titer Testing Results Drawn From Central Venous Lines and Venipuncture
- A Study Following Males With Haemophilia A on Prophylaxis With Esperoct®
- A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN
- A Study Following People With Haemophilia A and B, With or Without Inhibitors, When on Usual Treatment (Explorer™6)
- A Study in Children, Teenagers and Adults With Severe Hemophilia A Who Switched From Other Factor VIII Treatments to Adynovate
- A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
- A Study of ADVATE in People With Hemophilia A in India
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors
- A Study of Factor Inhibitors in Adult Patients With Hemophilia and Von Willebrand’s Disease in Upper Egypt
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors
- A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
- A Study of FVIII Gene Therapy for Hemophilia A
- A Study of SerpinPC in Participants With Hemophilia B (HemB) With Inhibitors
- A Study of Standard and Individualized Prophylactic Treatment With Advate in Men and Boys With Severe Hemophilia A
- A Study of TAK-660 in Surgical Procedures for People With Hemophilia A.
- A Study of the Impact of Hemophilia and Its Treatment on Brain Development, Thinking and Behaviour in Children With Hemophilia
- A Study to Compare the Blood Levels of Mim8 in Healthy Men When Administered With the DV3407-C1 Pen Injector or a Syringe and Cartridge
- A Study to Compare the Pharmacokinetics and Safety of Replenine®-VF, Replenine® or Other Factor IX in Haemophilia B
- A Study to Determine How a Virtual-reality Based Solution May Reduce the Treatment Burden of Children, Teenagers and Adults With Hemophilia A Who Receive Prophylactic Factor VIII Infusions
- A Study to Evaluate Seroprevalence and Seroconversion of Antibodies to Adeno-Associated Virus (AAV) in Patients With Hemophilia A
- A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia B
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With Inhibitors
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors
- A Study to Evaluate the Pharmacokinetics of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France
- A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B
- A Study to Evaluate the Safety and Efficacy of VGB-R04 in Adult Hemophilia B Patients
- A Study to Evaluate the Safety and Efficacy of ZS801 in Adult Hemophilia B Patients
- A Study to Evaluate the Safety and Pharmacokinetic of Recombinant Human Coagulation Factor VIII, Fc Fusion Protein for Injection
- A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors
- A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
- A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers
- A Study to Investigate the Safety and Efficacy of Optivate® in Children Under 6 Years of Age With Haemophilia A.
- A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Under the Age of 6 Years
- A Study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Patients Undergoing Major Surgery.
- A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients
- A Study to Learn About the Safety and Effectiveness of the Study Medicines Called Giroctocogene Fitelparvovec and Fidanacogene Elaparvovec
- A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
- A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice (“Real-World”), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
- A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI
- A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B
- A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
- A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A
- A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
- A Trial That Evaluates Disease Characteristics in Hemophilia B Adult Male Participants Receiving Prophylaxis With Standard of Care Factor IX Protein (FIX) Replacement Therapy
- A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A
- AAV Gene Therapy Screening/Observational Protocol (ECLIPSE)
- Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
- Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay
- Adherence to Treatment in Hemophilia
- ADVATE 2 mL Post-Authorization Safety Surveillance (PASS)
- ADVATE Post Authorization Safety Surveillance
- ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
- Adverse Event Data Collection From External Registries on Nonacog Beta Pegol
- Adverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol
- ADYNOVATE Drug Use-Results Survey
- Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia
- An Expanded Access Program of Emicizumab in Participants With Hemophilia A With Inhibitors
- An Exploration of the Impact of Gene Therapy on the Lives of People With Haemophilia and Their Families
- An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
- An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
- An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment
- An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
- An Open Study to Investigate the Safety and Efficacy of Optivate® in Haemophilia A Patients Undergoing Surgery.
- An Open Study to Investigate the Safety and Efficacy of Optivate® in Severe Haemophilia A Patients.
- An Open Study to Investigate the Safety and Efficacy of Replenine®-VF in Severe Haemophilia B Patients
- An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A
- An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A
- An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B
- An Open-study to Investigate the Safety and Efficacy of Replenine®-VF in Haemophilia B Subjects Undergoing Surgery
- Are There Differences Between Carriers of Haemophilia A and B?
- ASC-618 Gene Therapy in Hemophilia A Patients
- Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B
- Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
- Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A
- Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry
- Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A
- ATHN 2: Factor Switching Study
- ATHN 8: PUPs Matter Study
- ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- BAX 326 (rFIX) Continuation Study
- BAX 326 Pediatric Study
- BAX 326 Surgery Study in Hemophilia B Patients
- BAX 802 in CHA With Inhibitors
- BAX 826 Dose-Escalation Safety Study
- BAX 855 Continuation
- BAX 855 Dose-Escalation Safety Study
- BAX 855 Pediatric Study
- BAX 855 PK-guided Dosing
- BAY14-2222 Continuous Infusion in Surgeries
- BAY14-2222 Prophylaxis and Joint Function Improvement (Adults)
- BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A
- BAY81-8973 Pediatric Safety and Efficacy Trial
- BAY94-9027 PK Study Comparing to Another Long Acting Product
- BeneFIX Drug Use Results Survey [All-Case Surveillance]
- Biomarkers Serum Collection Methodology Pilot Study
- Biomechanical Determinants and Patterns Associated to the Pathophysiological Cascade of Ankle Arthropathy in Children With Haemophilia: Non-invasive In-vivo Measurement of Foot Joints in Children With Haemophilia During Gait.
- Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies
- Bleeding Symptoms of Carriers of Hemophilia A and B
- Bone Microarchitecture in Men With Hemophilia
- Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)
- BT200 in Hereditary Bleeding Disorders
- Canadian Hemophilia Prophylaxis Study
- Cardiovascular Disease (CVD) in Haemophilia
- Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
- Characterizing the Impact and Treatment of Reproductive Tract Bleeding on Women and Post-menarchal Girls With Bleeding Disorders
- China ADVATE PTP Study
- Clinical and Health-related Outcome of rFVIIIFc Prophylaxis
- Clinical Study of Recombinant Human Activated Coagulation Factor VII for Injection in Patients With Hemophilia With Inhibitor
- Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A
- Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A
- Clinical Trial of Factor XIII (FXIII) Concentrate
- Clot Formation and Clot Stability in Patients With Severe Haemophilia A
- Colorado Adult Joint Assessment Scale (CAJAS) Validation
- Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII
- Combining Registry Data in Haemophilia: TARGET H
- Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222
- Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
- Comparison of Different Prophylaxis Regimens for Moderate to Severe Hemophilia A Pediatric Patients
- Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients
- Comparison of Ideal vs. Actual Weight Base Factor Dosing
- Comparison of Prophylaxis and On-demand Treatment in Children With Moderate to Severe Hemophilia A
- Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects
- Cooperative Study of Factor VIII Inhibitors
- Could Physical Activity Help to Counteract the Blood Haemophilia Disturbance? A Pilot Study.
- Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
- Determinants and Consequences of the Transition to Adulthood Among Adolescents With Haemophilia
- Development of a Specific Measure for Assessing Adherence in Adult Patients With Hemophilia.
- Does the Thrombin Generation Test Performed During the Pharmacokinetic Profile of the Substitutive Factor VIII Bring Benefits to the Personalized Treatment of Pediatric Patients and Adult Hemophilia A Patients Under Prophylaxis ?
- Dosage and PD Study of Eftrenonacog-alfa
- Dose Confirmation Trial of AAV5-hFIXco-Padua
- Dose-Escalation Study Of A Self Complementary Adeno-Associated Viral Vector For Gene Transfer in Hemophilia B
- Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients
- Dose-Ranging Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 in Subjects With Severe Hemophilia A
- Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
- Drug Use Investigation of Kovaltry in Hemophilia A Patients
- Early Prophylaxis Immunologic Challenge (EPIC) Study
- Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
- Effectiveness of Psychological Interventions in Haemophilia
- Effectiveness of the uPatient Platform in Prophylactic Treatment in Hemophilia
- Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia A
- EFFEKT – Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS
- EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan
- Effekt-2 – Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America
- Efficacy and Cost Effectiveness of Pharmacokinetic Dosing in Haemophilia A
- Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A
- Efficacy and Safety of AlphaNine Versus BeneFIX in Patients With Severe Hereditary Haemophilia B
- Efficacy and Safety of IL-11 in DDAVP Unresponsive
- Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia
- Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Subjects With Haemophilia B
- Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A
- Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A
- Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10)
- Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A – A Continuation of Baxter Study 060101
- Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients
- Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A
- Efficacy and Safety Study of SCT800 for On-demand Treatment With in Patients With Hemophilia A
- Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
- Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
- Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
- Emicizumab PUPs and Nuwiq ITI Study
- Emotions in the Communication and Relationship Styles of Parents With Hemophilic Children.
- Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries
- Epidemiology and Immunology of Hemophilia A Inhibitors
- Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A
- Evaluate Efficacy and Safety of Recombinant Factor VIII （rFVIII）Treatment of Severe or Moderately Severe Hemophilia A
- Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
- Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
- Evaluating the Pharmacokinetics of NovoEight® (Turoctocog Alfa) in Relation to BMI in Subjects With Haemophilia A
- Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B
- Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia
- Evaluation of a Standardized Protocol for Thrombin Generation Assay
- Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO
- Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity
- Evaluation of Long-term Safety of ADYNOVI/ADYNOVATE (Antihaemophilic Factor [Recombinant] PEGylated, Rurioctocog Alfa Pegol) in Patients With Haemophilia A – An ADYNOVI/ADYNOVATE Post-Authorisation Safety Study (PASS)
- Evaluation of Patient and Physician Reported Reasons for Switching Factor VIII Replacement Therapies
- Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
- Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial
- Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A
- Evaluation of Static Postural Balance in Children With Hemophilia and Its Relationship With Joint Health
- Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
- Evaluation of the Training Program for Community Pharmacists for Dispensing Emicizumab (HEMLIBRA®) in France
- Ex Vivo Laboratory Assays Application for Therapy Tailoring in Patients With Severe Bleeding Disorders
- Exercise Versus DDAVP in Patients With Mild Hemophilia A
- Exit Interviews to Assess Impact of Infusion Frequency in Hemophilia A
- Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
- Extended Half-Life (EHL) Clotting Factor for Improving the Musculoskeletal Health of Patients With Hemophilia
- Extension at 10 Years of the: “Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A.”
- Factor IX as Adjunctive Therapy to Emicizumab (EMIX)
- Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes
- Females With Severe or Moderate Hemophilia A or B: A Multi-Center Study
- Females With Severe or Moderate Hemophilia A or B: an International Multi-center Study
- First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
- Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
- Gait Examination in Patients With Hemophilia in Austria
- GAS-Hem Feasibility Study
- Gene Therapy for Chinese Hemophilia A
- Gene Therapy for Chinese Hemophilia B
- Gene Therapy for Haemophilia A.
- Gene Therapy for Hemophilia B Patients Aged 12-18 Years Old
- Gene Therapy Study in Severe Haemophilia A Patients
- Gene Therapy Study in Severe Hemophilia A Patients With Antibodies Against AAV5
- Gene Therapy Trial for Platelet Derived Factor VIII Production in Hemophilia A
- Genetic Influence of Genetic Factors Influencing the Desmopressin’s Efficacy in Mild/Moderate Hemophilia A
- Genetic Susceptibility to Factor VIII Inhibitors
- German Pediatric Hemophilia Research Database
- Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia
- Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
- Global Hemostatic Methods in Hemophilia and Von Willebrand’s Disease
- Haemophilia and Bone Loss – PHILEOS Study
- Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
- Handheld Ultrasound (HHUS) for Home Use in Hemophilia
- He-move-philia, Lifestyle Intervention for Patients With Hemophilia
- Health Practice of Hemophilia Patiente Care During Pregnancy, Delivery and Newborn Children
- Health Related Quality of Life of Youth and Young Adults With Haemophilia A
- Health Related Quality of Life of Youth and Young Adults With Hemophilia A
- Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
- Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A
- Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A
- Hemophilia and Bone Metabolism: Study of Monocytic Populations and Inflammatory Proteins
- Hemophilia B Gene Therapy With AAV8 Vector
- Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform
- Hemophilia Inhibitor Previously Untreated Patient Study
- Hemophilia Mobile App Usability Pilot
- Hepatitis C in Clinically Discordant Hemophilic Siblings
- HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
- Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
- Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
- Immune Tolerance Induction in Haemophilia A Patients Using Wilate or Nuwiq
- IMMUNINE Pre-Treatment Study
- Impact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle Arthropathy
- Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
- Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
- Impact on French Physician’s Haemophilia Treatment Management Decision Based on Systematic Joint Examination
- Improved Factor VIII Inhibitor Evaluation
- In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
- INdividualized ITI Based on Fviii(ATE) Protection by VWF
- Individualized Prophylaxis for Severe Hemophilia A Children
- Individualizing Hemophilia Prophylaxis Using Thromboelastography
- Individually Tailored Prophylaxis in Patients With Severe Hemophilia A
- Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
- Inter Individual Variability in Initiation Pathway Activation and Regulation and Phenotypic Heterogeneity in Patients With Haemophilia A and B
- International PMS Study – KOGENATE Bayer
- Internet-based Educational Program to Promote Self-Management for Teens With Hemophilia
- Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
- Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients
- Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects
- Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects
- Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects
- Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
- iT-based Sports Therapy Application in Haemophilia
- Joint Health Study
- Joint Outcome Study
- Joint Status in Subjects With Severe Hemophilia A in Relation to Different Treatment Regimens
- KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
- Kogenate FS Regulatory Post-Marketing Surveillance
- Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B– An Observational Survey Analysis Study
- Lead-in Study to Collect Prospective Efficacy and Safety Data of Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Participants
- Learning to Live With Non-severe Haemophilia
- Lentiviral FIX Gene Therapy
- Lentiviral FVIII Gene Therapy
- Liver Biopsy In Haemophilia Gene Therapy
- Long-term Safety and Efficacy of BIVV001 in Previously Treated Patients With Hemophilia A
- Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B
- Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A
- Long-Term Safety and Efficacy of SPK-8011 in Males With Hemophilia A
- Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
- Long-term Safety and Efficacy Study of SPK-9001 in Individuals With Hemophilia B
- Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
- LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures
- LTFU for Gene Transfer Subjects With Hemophilia B
- Management of Health-Related QoL Impairment, Including Pain, Depression and Anxiety, in People With Haemophilia A and B
- Medication Exposure in Older Patients With Constitutional Hemorrhagic Disease
- Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients
- MOTHIF II : THERAPEUTIC MANAGEMENT AND USE OF CLOTTING FACTORS IN HEMOPHILIA A & B IN FRANCE II
- Motor Proficiency of People With Bleeding Disorders Using the BOT-2 (TM)
- Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
- Musculoskeletal Function in Hemophilia
- Mutation p.Ile112Thr : Discrepancy Between Factor IX Level and Bleeding Phenotype
- National Longitudinal Cohort of Hematological Diseases
- National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A
- National Survey of People With Haemophilia in Portugal
- Needs Assessment of Knowledge, Beliefs, and Attitudes of Patients With Hemophilia B About Gene Therapy
- Neutrophil-to-lymphocyte and Platelet-to-lymphocyte Ratio in Predicting the Incidence of Nausea and Vomiting
- Non Neutralizing Antibodies: Prevalence and Characterization
- Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.
- Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery
- Non-interventional Post-authorisation Study to Document the Immunogenicity, Safety, and Efficacy of NUWIQ
- Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient and Investigator Interviews
- Nonacog Alfa Prophylaxis And Treatment Of Bleeding Episodes In Previously Treated Patients With Hemophelia B
- Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors
- Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B
- Observatory of Patients With Haemophilia B Treated by IdElvion®
- Occupational Integration of Adults With Severe Haemophilia in France: a Study Based on the FranceCoag Cohort
- Once-A-Day Prophylaxis for Youth and Young Adults With Severe Hemophilia A
- Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
- Osteoporosis and Haemophilia
- Outcomes of Prophylaxis and On-demand Treatment for Severe Hemophiliacs and Collection of Baseline Data in Hemophiliacs in Taiwan
- Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast
- Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
- Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis
- Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
- Personalized Medicine for Canadians With Hemophilia
- Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
- PF-06741086 Long-term Treatment in Severe Hemophilia
- Pharmacokinetic Assessment of Standard Half-Life (SHL) FVIII, Extended Half-Life (EHL) FVIII, and Efanesoctocog Alfa (BIVV001) in Severe Hemophilia A
- Pharmacokinetic Characterization of the Hemophilia A Population in Spain Using myPKFiT®
- Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A
- Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A
- Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection
- Pharmacokinetic Study of SCT800 in Previously Treated Patients With Hemophilia A
- Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980
- Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale
- Pharmacokinetics Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Pharmacokinetics of rFVIIIFc at Two Vial Strengths
- Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State
- Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients
- Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A
- Phase 1 Safety, Pharmacokinetics And Pharmacodynamics Study Of Recombinant Factor VIIa Variant (813d) In Adult Subjects With Hemophilia
- Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B
- Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
- Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
- Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX Deficiency
- Phase I/IIa Study of FIXFc in Hemophilia B Patients
- Phase III Expansion Trial for Determining the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A
- Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
- PHYSICAL ACTIVITY AND FVIII CLEARANCE: RELEVANCE FOR PERSONALIZED THERAPY IN SEVERE HAEMOPHILIA A (PHYSEMO)
- Physical Activity and FVIII Elimination: Relevance to Personalized Therapy in Severe Hemophilia A
- Pilot Evaluation of a Motivational Interviewing Intervention Targeting Adherence Behaviors in Youth With Hemophilia
- PK Driven Prophylaxis for Hemophilia A
- Platelet Function in Patients With Hemophilia A
- POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies
- Post Marketing Observational Study of Reformulated BeneFIX
- Post Marketing Study in Haemophilia B Patients Using Nonafact® (Human Coagulation Factor IX)
- Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B
- Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A
- Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database
- Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea
- Post-marketing Surveillance (Use Result Surveillance) With Refixia®
- Post-Marketing Surveillance (Use-results Surveillance) With Esperoct®
- Posture Analysis for Adolescent Patients With Haemophilia
- Prevalence of Autistic Spectrum Disorder (ASD) in Children With Haemophilia
- Preventing Inhibitor Recurrence Indefinitely
- Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
- Project to Update the Study of Congenital Haemophilia in Spain
- Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia A
- Prophylaxis Versus on Demand Treatment for Children With Hemophilia A
- Prophylaxis Versus On-demand Therapy Through Economic Report
- Prospective Biomarkers of Bone Metabolism in Hemophilia A
- Prospective Registry of European Hemophilia B Patients Receiving BeneFIX® for Usual Use
- Prospective Study of HIV Infection in Hemophiliacs
- Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products
- Psychology and Physiotherapy Approach of Chronic Pain in Patients With Hemophilia
- Psychometric Validation of the Hemophilia Functional Ability Scoring Tool (Hemo-FAST)
- Pulsed Electromagentic Field in Haemophilia
- Quality of Life and Adjustment Among Siblings of Children and Adolescents With Severe Hemophilia
- Quality of Life in Adult Patients With Severe Haemophilia in Turkey
- Quality of Life Study of Helixate NexGen
- Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A
- Recombinant Factor VIIa (NovoSeven) on Restoring Coagulation Activation
- Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen
- Register of Patients With haEmophilia A tReated With Afstyla®
- Registry For Patients Treated With BeneFix In Usual Care Setting In Germany
- Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)
- Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced)
- Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period
- Resistance Training With Blood Flow Restriction in Hemophilia
- Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients in China With Moderate to Severe Hemophilia A
- Retrospective Study in Chinese Pediatric Hemophilia A Patients With rFⅧ Contained Regular Prophylaxis
- Risk Models to Optimise Prophylaxis Schedules in Children With Haemophilia
- RIXUBIS Drug Use-Result Survey (Japan)
- RIXUBIS PMS India (RIXUBIS PMS)
- Russian Kogenate Pediatric Study
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
- Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A
- Safety and Dose Escalation Study of an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia A Participants
- Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B
- Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia
- Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A
- Safety and Efficacy in a ReAl-Life Study in Patients With Haemophilia Treated wIth NovoEight® for Surgery
- Safety and Efficacy of BAY94-9027 in Previously Treated Male Children With Haemophilia A
- Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China
- Safety and Efficacy of Long-term Treatment With SCT800 in Previously Treated Hemophilia A Patients.
- Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
- Safety and Efficacy of NNC-0156-0000-0009 in Haemophilia B Patients
- Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B
- Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor
- Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
- Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A
- Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects
- Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
- Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A
- Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A
- Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery
- Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B
- Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B
- Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A
- Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
- Safety and Tolerability of VGB-R04 in Patients With Haemophilia B
- Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B
- Safety of a New Type of Treatment Called Gene Transfer for the Treatment of Severe Hemophilia B
- Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B
- Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
- Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
- Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.
- Safety, Efficacy and PK of BIVV001 in Pediatric Patients With Hemophilia A
- Safety, Efficacy Evaluation of Recombinant Coagulation Factor VIII Injection in Subjects With Hemophilia A.
- Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Recombinant FVIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years of Age With Severe Hemophilia A
- Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A
- Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
- Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients
- Satisfaction Regarding the Dispensing of Emicizumab (HEMLIBRA®) for Patients With Haemophilia A in France
- SCOPE HIM SCOPE HIM
- Severe Hemophilia Non-Interventional Study
- Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients
- Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients at a Dose of 4E13 vg/kg
- Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
- Socialization of Adult Men With Congenital Hemophilia A or B
- Sonography and Haemophilia
- Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
- Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B
- Study Evaluating Allergic Reactions To Benefix In Hemophilia B Patients
- Study Evaluating Approach to Treatment of Haemophilia A and B in Spain
- Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
- Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
- Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX
- Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B
- Study Evaluating Inhibitor Specificity in Hemophilia A
- Study Evaluating Liver Transplantation in Haemophilia Patients in Spain
- Study Evaluating of Recombinant Human Factor IX (BeneFIX) and a New Formulation of BeneFIX (rFIX-R) in Moderate to Severe Hemophilia B
- Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects
- Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects
- Study Evaluating Pharmacovigilance Of Refacto AF
- Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
- Study Evaluating ReFacto AF in Severe Hemophilia A
- Study Evaluating Refacto For Pharmacovigilance
- Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
- Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
- Study Evaluating rFIX; BeneFIX® in Hemophilia B
- Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
- Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings
- Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age
- Study Evaluating The Safety Of Xyntha In Usual Care Settings
- Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)
- Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients
- Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A
- Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B
- Study of Ataluren (PTC124®) in Hemophilia A and B
- Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development
- Study of Biostate® in Children With Hemophilia A
- Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
- Study of Emicizumab Prophylaxis in Participants With Hemophilia A With or Without Inhibitors Undergoing Minor Surgical Procedures
- Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor – RES.I.S.T. Naive
- Study of FVIIa Variant BAY86-6150 (B0189) in Subjects With Moderate or Severe Hemophilia Types A or B With or Without Inhibitors
- Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A
- Study of Next-Generation Recombinant Factor IX Variant in Adult Subjects With Hemophilia B
- Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A
- Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients – A Continuation of Clinical Study 069901
- Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A
- Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
- Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B
- Study of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in Participants With Hemophilia B
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B
- Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B
- Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B
- Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A
- Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII
- Study of rFVIIIFc for ITI in Haemophilia A Patients With Inhibitors Who Have Failed Previous ITI Therapies
- Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting
- Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B
- Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes.
- Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador
- Study to Compare How the Body Distributes and Excretes the Drugs Jivi (BAY 94-9027) and Adynovi in Patients With Severe Hemophilia A (Bleeding Disorder Resulting From a Lack of Blood Clotting Factor VIII)
- Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B
- Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B
- Study to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B
- Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A
- Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia
- Study to Evaluate the Efficacy and Safety of PF-07055480 in Moderately Severe to Severe Hemophilia A Adults
- Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A
- Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A
- Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A
- Study to Gain More Information on How Safe and Effective Jivi Works in Patients With Severe Hemophila A (Post-marketing Investigation)
- Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII
- Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)
- Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
- Study to Learn More About the Safety of Drug Jivi Over a Long Period of Time in Previously Treated Patients With Hemophilia A (Bleeding Disorder Resulting From a Lack of FVIII) Who Are Receiving Jivi Regularly at Their Treating Doctors to Prevent Bleeding
- Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a “Shuttle”.
- Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
- Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
- Survey Evaluating the Psychosocial Effects of Living With Haemophilia
- Survey of Inhibitors in Plasma-Product Exposed Toddlers
- TFPI Levels in Haemophilia A and B Patients
- The Dynamic Interplay Between Bleeding Phenotype and Baseline Factor Level in Moderate and Mild Hemophilia A and B
- The Effect of Functional Activities and Balance Ability With Taping in Subjects of Hemophilia
- The Effect of Patient Counseling on Adolescent Hemophilia Patient Compliance With Bleeding Logs
- The Effectiveness of Recombinant Fusion Protein Linking Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients Switching From Previous Factor IX Treatment
- The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia
- The Effects of Core Stabilization Exercises in Addition to Balance Exercises in Adult Hemophilia Patients on Balance, Quality of Life, Lower Limb Muscle Strength and Functional Level
- The Effects of Exercise Training in Children With Hemophilia
- The Efficacy and Safety of SerpinPC in Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
- The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.
- The Efficacy and Safety of ZS802 in Chinese Hemophilia A Patients.
- The Hemophilia Ultrasound Project
- The Influence of “Karate” on Bleeding in Hemophilic Patients.
- The Safety and Tolerability of SerpinPC in Healthy Men and in Men With Severe Blood Disorders (Haemophilia A and B)
- The Safety of Hemlibra SC Injection in Korean Patients With Hemophilia A
- The World Federation of Hemophilia Gene Therapy Registry
- Therapeutic Exercise in Patients With Hemophilia
- Thrombin Generation Numerical Models Validation in Haemophilic Case
- Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
- To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
- To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives
- Treatment of Hemophilia A Patients With FVIII Inhibitors
- Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF – A Swedish Cohort Study
- Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
- Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B
- Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
- Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
- Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
- Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration
- Turoctocog Alfa in Haemophilic Italian Patients: Protection and Engagement in Recreational Activities
- UK – EHL Outcomes Registry
- Understanding Hemophilia A and B Drug Dosage Administration Patterns
- UPLC-MS/MS Monitoring of Emicizumab Therapy
- Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
- Validation and Reliability of the CHO-KLAT in Turkish
- Validation of a Specific Measure for Assessment of Compliance With Treatment in Patients With Hemophilia
- Validation of Questionnaires HAL and HEP
- Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients
- Viral Kinetics in HCV Clearance in Subjects With Hemophilia
- Virtual Reality for Hemophilia
- Web Accessible Population Pharmacokinetics Service – Hemophilia: Sources of Variability
- Web-based Application for the Population Pharmacokinetic Service – Phase 1
- Weight-based Dosing in Hemophilia A
- What is the Feasibility of the ISTEP Exercise Test in Boys With Haemophilia
- World Bleeding Disorders Registry
- Clinical, Functional and Musculoskeletal Differences Between Adult Patients With Hemophilia and Their Healthy Peers
- COVID-19 Quarantine on Musculoskeletal Status in Hemophilia
- Effect of Exercise in Pediatric Hemophilia
- Pain and Joint Status With Psychosocial Factors in Patients With Hemophilia
- Quality of Life in Hemophilia by Clinical Scoring System (FISH)Score
- Rofecoxib Efficacy and Safety Evaluation Trial in Hemophilic Arthropathy
- Sarcopenia and Osteoporosis in the Patients With Hemophilia
- Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
- Vitamin D Deficiency and Body Composition in the Patients With Hemophilia
- A Study of Long-term Treatment With Deferasirox in Patients With Beta-thalassemia and Transfusional Hemosiderosis
- Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
- Efficacy Study in Removing Excess Iron From the Heart
- Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
- Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)
- Non-invasive Quantification of Liver Iron With MRI
- Pharmacogenetic Study in Patients Received Iron Chelating Agent
- Safety, Tolerability, and Efficacy of Deferasirox in MDS
- Clinical Study on Strategy for Refractory Henoch-Schönlein Purpura
- Cohort Study on Traditional Chinese Medicine Diagnosis and Treatment of Children With Henoch-Schonlein Purpura Nephritis
- Efficacy of Steroid Versus Steroid Plus Cyclophosphamide for Severe Henoch-Schoenlein Purpura
- Mycophenolate Mofetil (MMF) Versus Intravenous CTX Pulses in the Treatment of Adult Severe HSPN
- Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura
- The Research of Standard Diagnosis and Treatment for HSPN in Children
- The Research of Standard Diagnosis and Treatment for HSPN With Mild Proteinuria in Children
- The Research of Standard Diagnosis and Treatment for Severe HSP in Children
- A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy
- A Multi-Center Group to Study Acute Liver Failure in Children
- A Nutritional Approach to Minimal Hepatic Encephalopathy
- A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Renal Failure
- A Randomized Open-label Trial of Deprescribing Proton Pump Inhibitors to Reduce the Risk of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Creation
- A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study]
- A Study of Controlled Lactulose Withdrawal
- A Study of MHE in Patients With Liver Diseases
- A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy
- Acetyl-L-Carnitine Reduces Depression and Improves Quality of Life in Patients With Minimal Hepatic Encephalopathy
- Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy
- Allopurinol Versus Simvastatin to Prevent Complications of Liver Cirrhosis
- Antioxidants and Zinc Improving Minimal Hepatic Encephalopathy In Truck Drivers; a Pilot Study
- AST-120 Used to Treat Mild Hepatic Encephalopathy
- Bioelectrical Impedance Vector Analysis in Cirrhotic Patients
- Brain Energy Metabolism in Patients With Chronic Liver Disease and Impaired Central Nervous System
- Brain Imaging in Patients With Chronic Liver Disease and Functional Impairment.
- Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate
- Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE)
- Cerebrovascular Reactivity in Hepatic Encephalopathy
- Characterization of Metabolomic Fingerprints in Patients With Acute Liver Failure and Acute-on-chronic Liver Failure With Hepatic Encephalopathy
- Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy
- Comparing Nifuroxazide Plus Lactulose With Lactulose Alone in the Treatment of Hepatic Encephalopathy
- Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy
- Comparison Between Lactulose and Lactulose-Paraffin in Cirrhotic Patients
- Default Mode Network fMRI Maps as a Predictive Index of Hepatic Encephalopathy Outcome
- Diagnosing Minimal Hepatic Encephalopathy
- Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement
- Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)
- Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE
- Effect of Brief Dietary Intervention on Ammonia Levels
- Effect of Lactose in Patients With Chronic Liver Disease and Minimal Hepatic Encephalopathy
- Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life
- Effect of Midodrine and Albumine in the Prevention of Complications in Cirrhotic Patients Awaiting Liver Transplantation
- Effect of Music on Attention and Prospective Memory in Hepatic Encephalopathy
- Effect of Probiotics in Treatment of Minimal Hepatic Encephalopathy (MHE) and Health Related Quality of Life
- Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy
- Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients
- Effect of Yogurt on Minimal Hepatic Encephalopathy
- Effects of Branched-Chain Amino Acids on Muscle Ammonia Metabolism in Patients With Cirrhosis and Healthy Subjects
- Effects of Proteins in Patients With Cirrhosis and Prior Hepatic Encephalopathy
- Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
- Efficacy and Safety of Fecal Microbiota Transplant for Secondary Prophylaxis of Hepatic Encephalopathy
- Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
- Efficacy and Safety Study of Ammonul® in Patients With Grade 3 or 4 Hepatic Encephalopathy
- Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)
- Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis
- Efficacy of Combined Oral L-Ornithine-L-Aspartate and Lactulose in Patients With Hepatic Encephalopathy
- Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy
- Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
- Efficacy of L-Ornithine-L-Aspartate in Cirrhotics With Hepatic Encephalopathy
- Efficacy of Sildenafil in the Improvement of Cognition and Quality of Life in Patients With Cirrhosis of Liver. A Proof of Concept Study.
- Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy.
- Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy
- Establishment of the Human Intestinal and Salivary Microbiota Biobank – Gastrointestinal Diseases
- Explore the Efficacy and Safety of FMT With Different Bacterial Doses in the Treatment of Hepatic Encephalopathy
- Eye Movement Testing for Diagnosing Encephalopathy in Patients With Liver Disease
- Factors Associated With End Stage Liver Disease
- Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis
- Fecal Microbiota Transplant as Treatment of Hepatic Encephalopathy
- Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study
- Fecal Transplant for Hepatic Encephalopathy
- Fecal Transplant in Recurrent Hepatic Encephalopathy
- Flicker App for Minimal Hepatic Encephalopathy
- FMT in Cirrhosis and Hepatic Encephalopathy
- GELSECTAN® and Covert Hepatic Encephalopathy
- HEAL STUDY (Hepatic Encephalopathy and Albumin Study)
- HepQuant to Predict Hepatic Encephalopathy After TIPS
- Hyperproteic Diet Plus Lactobacillus Reuteri and Nitazoxanide in Minimal Hepatic Encephalopathy
- Immune Profile, Neuronal Dysfunction, Metabolomics and Ammonia in Therapeutic Response of HE in ACLF
- Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)
- Intravenous Branched Chain Amino Acids for Hepatic Encephalopathy in ACLF
- Investigational Microbiota Restoration Therapeutic for Hepatic Encephalopathy
- iPod Games in Hepatic Encephalopathy
- L-ornithine L-aspartate in Overt Hepatic Encephalopathy
- Lactulose for the Prevention of Hepatic Encephalopathy in Cirrhotic Patients With Upper Gastrointestinal Hemorrhage
- Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
- Late Evening and Early Morning Protein Supplement to Reduce Readmissions for Hepatic Encephalopathy
- Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
- Manganese in Women With Encephalopathy
- Metformin Experience on Minimal Hepatic Encephalopathy
- Microbial Resistance of Rifaximin in Hepatic Encephalopathy
- Minimal HePatic Encephalopathy Among CiRrhotics. A Cross SEctional, Clinico-EpidEmiological, Multi-Centre, Study in Patients of PakisTan
- MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function
- MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
- Monitoring of Encephalopathy in Cirrhotic Patients Admitted in Intensive Care
- N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure
- Oral Acetyl-L-Carnitine Therapy Reduces Fatigue In Hepatic Encephalopathy
- Oral Fecal Transplant in Cirrhosis
- PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy
- PEG3350 in ACLF With Hepatic Encephalopathy
- Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
- Plasma Free Amino Acids in Patients With Hepatic Encephalopathy
- Polyethylene Glycol Versus Lactulose on Hepatic Encephalopathy in Patients With Cirrhosis;(PEGHE Trial)
- Post Transjugular Intrahepatic Portosystemic Shunt (Tips) Albumine Infusion to Prevent Hepatic Encephalopathy
- Prediction of Mortality in Patients Waiting for Liver Transplantation Through Brain Magnetic Resonance Imaging
- Prediction of Post-TIPS Hepatic Encephalopathy in Patients With Liver Cirrhosis
- Prevention of Hepatic Encephalopathy With Mobile Application Based Lactulose Titration
- Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis
- Probiotic Lactobacillus GG (LGG) in Patients With Minimal Hepatic Encephalopathy
- Prognostic Significance of Fatty Liver Disease in Bariatric Patients
- Quantitative Determination of Brain Water Content in Patients During and After Hepatic Encepalopathy
- Real World Outcomes Study of Hepatic Encephalopathy Patients’ Experience on Rifaximin (PROSPER)
- Reversibility of Minimal Hepatic Encephalopathy Following Liver Transplantation
- RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy – A Randomized, Controlled Trial
- Rifamycin in Minimal Hepatic Encephalopathy
- Rifaximin in Minimal Hepatic Encephalopathy
- Rifaximin Plus Lactulose Versus Lactulose Alone for the Treatment of Hepatic Encephalopathy: a Double Blind Randomized Trial
- Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
- Rifaximin’s Effect on Covert Hepatic Encephalopathy in Cirrhosis Patients With Small Intestinal Bacterial Overgrowth and Gastrointestinal Dysmotility
- Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure
- Role of MRI in Detection of Minimal Hepatic Encephalopathy
- S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
- Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
- Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy
- Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis
- Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
- Secondary Prophylaxis of Hepatic Encephalopathy With a Probiotic Preparation
- Speech in Hepatic Encephalopathy (HE)
- Study of Lactulose in Children With Chronic Liver Disease
- Study of Rifaximin in Minimal Hepatic Encephalopathy
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
- Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis
- Tackling 30-day Readmissions in Patients With Cirrhosis: The SALTYFOOD Trial
- The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy.
- The Effect of a Large-volume Paracentesis on Fatigue, Sleep, and Quality of Life in Cirrhosis
- The Effect of Induced Hyperammonaemia on Sleep and Melanopsin-mediated Pupillary Light Response in Patients With Liver Cirrhosis
- The Effect of Prometheus (R) Liver Support Dialysis on Cerebral Metabolism in Acute Liver Failure
- The Effects of Nitazoxanide in Hepatic Encephalopathy
- The Efficacy and Safety of Rifaximin Treatment
- The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy
- The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy.
- The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy
- Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy
- Timing of Acute Palliative Care Consultation in Critically Ill Patients
- Transcranial Doppler Ultrasound and Minimal Hepatic Encephalopathy
- Treatment of Hepatic Encephalopathy With Flumazenil and Change in Cortical GABA Levels in MRS
- Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics
- VE303 for Treatment of Hepatic Encephalopathy (HE)
- A Study of Experimental Medication BMS-986036 Given to Healthy Participants
- A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis
- A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C
- A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV
- Assessment of Hepatic Fibrosis by Shear Wave Elastography in Patients With Liver Malignancy: A Prospective Single-center Study
- Clinical Trial for Evaluation of Treatment With Multiple Infusions of Mononuclear Bone Marrow Cells in Patients With Chronic Liver Diseases
- Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium
- Human Umbilical Cord-Mesenchymal Stem Cells for Hepatic Cirrhosis
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment
- Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA)
- Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices
- Prediction of Significant Hepatic Fibrosis in HCV Carriers With PNALT by SAPI- A Validation Study
- Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD
- 5-day Defibrotide Treatment for Hepatic SOS/VOD
- Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation
- Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver
- Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study
- Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoetic Stem Cell Transplant Patients
- Detection of Sinusoidal Obstruction Syndrome With Ultrasound After Allogeneic HSCT
- Efficacy of N-acetylcysteine Versus Placebo as Prophylaxis of Sinusoidal Obstruction Syndrome in Patients Undergoing Hematopoietic Stem Cell Transplantation
- European VOD Registry
- Liver Stiffness Measurement Predicts VOD/SOS Development (ELASTOVOD ITALIAN MULTICENTRIC STUDY)
- Pediatric Trial Investigating the Incidence & Outcome of Veno-Occlusive Disease With the Prophylactic Use of Defibrotide
- Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
- Sinusoidal Obstruction Syndrome for Stem Cell Transplant Patients Biomarker Study
- Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
- Ultrasound Elastography to Predict Development of SOS
- Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome
- Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients
- A Long Term Follow-up Study of Patients From the REP 301 Protocol
- A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
- A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
- A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
- A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection
- An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)
- Disease Loads and Status of Treatment
- Epidemiology of Hepatitis B, C and D and HIV Along the Maroni River Bordering French Guiana and Suriname (MaHeVi)
- Epidemiology of Hepatitis B, C and Delta in Reunion Island
- Ezetimibe for Patients With Chronic Hepatitis D
- HIDIT II – PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
- Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
- Lonafarnib for Chronic Hepatitis D
- Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
- Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
- Pegylated Interferon to Treat Chronic Hepatitis D
- Phase 2b Study of Bulevirtide (With Peginterferon Alfa-2a) in Patients With CHD
- Phase 3 Study of Bulevirtide in Patients With CHD
- Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV
- Proof-of-concept Study Evaluating the Safety and Efficacy of EBP921 in Delta Hepatitis (HDV)
- SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection
- Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV)
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a
- Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta
- The Hepatitis Delta International Network
- Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
- Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
- A Clinical Trial to Evaluate a Recombinant Hepatitis E Vaccine in Healthy Adults
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
- A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
- A Study on the Recombinant Hepatitis E Vaccine (Escherichia Coli) (Accelerated Vaccination Schedule)
- Clinical Trial of Recombinant Hepatitis E Vaccine
- Evaluation of Orthohepevirus C Infection as an Emerging Cause of Zoonotic Origin Disease
- HepNet Pilot Trial: Multicenter Trial for the Treatment of Chronic Hepatitis E With Sofosbuvir (SofE)
- HEV in Patients With Acute Non-A, Non-B, Non-C Hepatitis in Al-Rajhy University Hospital for Liver
- Morbidity and Mortality of Hepatitis E Virus Infections in Belgium
- Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®）
- Ribavirin for Severe Acute and Chronic Hepatitis E Virus Infection.
- Role of Cytokines in Hepatitis E Virus Infection During Pregnancy
- Safety Study of Hepatitis E Vaccine (HEV239)
- Seroprevalence Hepatitis E Infection in Healthy Blood Donors
- Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb)
- Seroprevalence of Hepatitis E in People With an Organ Transplant
- Study of the Immunogenicity and Efficacy of HBsAg Vaccine in Combination With Standard Antiviral Therapy With HB110E
- The Epidemiology of Hepatitis E Virus Infection in Israel and Potential Risk Factors
- Biomarkers in Tissue Samples From Young Patients With Liver Cancer
- Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery
- Combination Chemotherapy With or Without Amifostine in Treating Young Patients With Liver Cancer
- Combined Modality Therapy in Hepatoblastoma: South Egypt Cancer Institute Experience
- Deep Learning Magnetic Resonance Imaging Radiomics for Diagnostic Value of Hepatic Tumors in Infants
- Diagnostic Accuracy of PIVKA-II Combining With Alpha-Fetoprotein in Hepatic Tumor
- ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
- Evaluation of Lung Metastases Based on Ultrashort Echo Time MRI
- GastroIntestinal Cancer in Children and Adolescents
- Hepatoblastoma Biology Study and Tissue Bank
- Paediatric Hepatic International Tumour Trial
- Relapsed and Refractory Hepatoblastoma: A Prospective Registry and Liver Tumor Research Consortium Initiative
- Sequential PD-1/PD-L1 Inhibitor and LENvatinib in TLCT and Refractory Hepatoblastoma After Chemotherapy
- T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer (TEGAR)
- Clinical and Molecular Correlations in Spinocerebellar Ataxia Type 10 (SCA10)
- Core Stability Exercises and Hereditary Ataxia
- Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia
- Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Hereditary Ataxia